|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Aduro BioTech
| | | Phone: | (510) 848-4400 ×110 | Fax: | (510) 848-5614 | Year Established: | 2008 | Ticker: | ADRO | Exchange: | NASDAQ | Main Contact: | Stephen T. Isaacs, President & CEO | | Other Contacts: | Hans van Eenennaam, Executive VP, Antibody Research Jennifer Lew, CFO Aimee Luck Murphy, VP, Clinical Development & Operations Blaine Templeman, Executive VP & General Counsel Dirk G. Brockstedt, Ph.D., Senior VP, R&D Liana Wu, VP, Commercial Aimee Murphy, Senior Director, Development & Operations Andrea van Elsas, Ph.D., CSO Dirk G. Brockstedt, Executive VP, R&D Michele DeVries, VP, Regulatory Affairs
| | Company Description | Aduro BioTech, formed through the merger of two early stage cancer therapy companies: Oncologic and Triton BioSystems, is a privately held, clinical-stage biotechnology company focused on the development immunotherapies for infectious diseases and cancer.
Aduro BioTech utilizes Listeria monocytogenes, a type of bacteria, to re-educate the immune system so that it can recognize and attack pathogen infected cells and cancer. | |
|
|
|
|
|